News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Aspect Biosystems and Novo Nordisk have announced a collaboration, development, and licence agreement to develop bioprinted tissue therapeutics to replace or repair biological functions in the body: with the aim of creating a ‘new class of truly...
A Phase 1 trial found that a freeze-dried, temperature-stable experimental tuberculosis vaccine was safe, well-tolerated and elicited robust antigen-specific serum antibody and Th1-type cellular immune responses.
Biogen, Sartorius and Recipharm are among the companies welcoming new faces to top jobs.
The modification of an existing collaboration agreement with AstraZeneca gives Sanofi full commercial control of RSV antibody Beyfortus (nirsevimab) and 'enhanced agility' in the US market.
The biotech startup Immune Bridge has bagged $12 million in a seed financing round to drive the development of natural killer (NK) cells that can be used in cell therapies for cancer.
Moderna has announced new mRNA vaccine development programs: with the Lyme disease candidate representing an expansion of the company's mRNA tech to target bacterial pathogens.